EPIC-HR Evaluates Nirmatrelvir-Ritonavir for COVID-19
PulmCCM
JANUARY 29, 2022
The first large, now completed, clinical evaluation of NIR-RIT is the EPIC-HR study , or the Evaluation of Protease Inhibition for COVID-19 in High-Risk patients. Stated another way, if you treat 17 patients meeting the inclusion and exclusion criteria for EPIC-HR, an instance of hospitalization or death due to COVID-19 is prevented.
Let's personalize your content